Treatment | Page 343 of 465

Glaucoma :: Patients at Risk for Glaucoma Will Benefit From Risk Assessment Tool

A combined analysis of two landmark clinical glaucoma trials — the Ocular Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study (EGPS) — confirms the benefit of a five-year risk assessment model to help ophthalmologists better predict which patients have an increased risk of developing glaucoma. Glaucoma is the second leading cause of blindness in the world, affecting approximately 70 million people, and can lead to blindness if left untreated. These new data were presented this week at the annual American Academy of Ophthalmology meeting.

Cholesterol :: Intensive Lipitor Therapy Reduced Heart Attack

Results of a new analysis showed that patients who have heart disease and chronic kidney disease who took Lipitor? (atorvastatin calcium) Tablets (80 mg) reduced their risk of heart attack and stroke by 32 percent compared with patients taking the 10 mg dose of Lipitor. This analysis of a subset of patients from the five-year TNT (Treating to New Targets) study was designed and completed after the end of the trial. The data were presented here today at the Annual Scientific Sessions of the American Heart Association.

Asthma :: Fewer hospitalizations among asthma patients treated with Advair Diskus

An observational study of more than 64,000 asthma patients demonstrated that patients receiving treatment with Advair Diskus (fluticasone propionate and salmeterol inhalation powder) had a significant risk reduction in emergency department visits due to asthma versus patients treated with fluticasone propionate (FP) alone.

Asthma :: Majority of asthma patients remain uncontrolled

A survey of more than 1,300 asthma patients found that the majority of respondents (61 percent) had uncontrolled asthma based on their Asthma Control Test (ACT) score, and nearly one-third (29 percent) of those were not aware that their asthma was uncontrolled. Uncontrolled asthma may place patients at risk for increased symptoms, sudden attacks, hospitalization and even death from asthma.

Lack of understanding about common, life-threatening lung disease that affects millions

Results of a new survey conducted among more than 1,000 Americans age 45 and older reveal that most adults are not concerned about Chronic Obstructive Pulmonary Disease (COPD), a lung disease that is the fourth leading cause of death in the U.S. According to the survey, only 1 in 10 adults could correctly identify what COPD is, and only 4 percent consider COPD to be a health condition they worry ?the most? about getting, compared against other common chronic diseases, such as Alzheimer?s disease, heart disease, diabetes, or lung cancer. However, more people die from COPD than breast cancer or prostate cancer each year.

Asthma :: GlaxoSmithKline welcomes new GINA guidelines for Asthma Management and Prevention

GlaxoSmithKline (GSK) today welcomes new guidelines for Asthma Management and Prevention released today from The Global Initiative for Asthma (GINA). The guidelines emphasise that the overall aim of asthma treatment is to achieve and maintain long-term control of the disease and introduce a new classification of asthma based on levels of control1. Recommended treatment action is then based on the patient?s level of control.

Macular Degeneration :: Novartis’ Lucentis, ranibizumab approved in Europe for severe vision loss

Novartis has received a positive opinion supporting European Union regulatory approval for Lucentis? (ranibizumab) as a new treatment option for patients with the “wet” form of age-related macular degeneration, the leading cause of severe vision loss in people over age 50 in the western world.

Hypertension :: Novartis’ Exforge, valsartan approved in Europe for patients with high blood pressure

Novartis announced today a positive opinion supporting European Union approval of Exforge? (valsartan/ amlodipine besylate) as a new treatment option for patients with high blood pressure.

Fungal Infections :: Novartis’ Mycograb might be approved in Europe for serious fungal infections

Novartis announced today that it plans to submit additional information to the Committee for Medicinal Products for Human Use (CHMP) in Europe to support the approval of Mycograb?, in development as a treatment for life-threatening fungal infections, after the CHMP issued a negative recommendation.

Flu :: Statement – Label changes for Tamiflu – Roche

Tamiflu (oseltamivir phosphate) was demonstrated in clinical trials to be a safe and effective medication for influenza prevention and treatment. Tamiflu was approved in 1999 and has been used by more than 42 million people in over 80 countries.